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Background: Most carcinomas are prone to metastasize despite successful treatment of the primary tumor. One way
to address this clinical challenge may be targeted therapy with α-emitting radionuclides such as astatine-211 (211At).
Radioimmunotherapy utilizing α-particle emitting radionuclides is considered especially suitable for the treatment of
small cell clusters and single cells, although lesions of different sizes may also be present in the patient. The aim of this
study was primarily to evaluate the toxicity and secondarily in vivo efficacy of a 211At-labeled monoclonal antibody
(mAb) directed against colon carcinoma with tumor diameters of approximately 10 mm.
Methods: Eighteen rats with subperitoneal syngeneic colon carcinoma were allocated to three groups of six animals
together with three healthy rats in each group. The groups were injected intravenously with either 150 μg of
unlabeled mAbs (controls) or 2.5 or 5 MBq 211At-mAbs directed towards the Lewis Y antigen expressed on the cell
membrane of several carcinomas. Tumor volume, body weight, and blood cell counts were monitored for 100 days
after treatment.
Results: Local tumors were non-palpable in five out of six rats after treatment with both activities of 211At-mAbs,
compared to one out of six in the control group. At the study end, half of the animals in each group given 211At-BR96
and one animal in the control group were free from disease. Radioimmunotherapy resulted in dose-dependent,
transient weight loss and myelotoxicity. Survival was significantly better in the groups receiving targeted alpha therapy
than in those receiving unlabeled mAbs.
Conclusions: This study demonstrates the possibility of treating small, solid colon carcinoma tumors with α-emitting
radionuclides such as 211At bound to mAbs, with tolerable toxicity.
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Although the treatment of primary tumors is often success-
ful, metastatic disease is the major cause of cancer-related
mortality [1]. There is thus a need for new treatment mo-
dalities targeting metastases in order to improve the sur-
vival of patients suffering from malignant tumors.
During radioimmunotherapy, radionuclides are directed
to tumor lesions by specific targeting using monoclonal
antibodies (mAbs) as carrier molecules. The concept has
resulted in two FDA-approved radioimmunoconjugates,
90Y-ibritumomab tiuxetan and 131I-tositumomab, for the* Correspondence: sophie.eriksson@med.lu.se
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in any medium, provided the original work is ptreatment of non-Hodgkin's lymphoma. However, several
studies have shown radioimmunotherapy to be less effec-
tive in the treatment of larger solid tumors [2,3], and the
focus has therefore changed to treating small lesions
including metastases [4,5]. Due to the relatively long path
length of β-particles, β-emitting radionuclides are gene-
rally considered unsuitable for targeting microscopic tu-
mors as much of the radiation will be deposited outside
the tumor. Alpha-emitting radionuclides have a much
shorter particle path length (typically <100 μm) resulting in
less irradiation of healthy tissue [6]. One such α-emitting
radionuclide is 211At, which has a half-life of 7.2 h and a
particle range in soft tissue of 55 to 80 μm. Promising
results have been obtained in preclinical studies on 211At-
labeled mAbs in models of, e.g., leukemia [7,8] and ovarianan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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glioma and ovarian carcinoma [13,14].
Colon carcinoma is among the most common cancer
diseases and is prone to metastasize [15]. In vivo studies on
radioimmunotherapy with the β-emitting radionuclide 177Lu
(maximal range in soft tissue, 1.8 mm) with the aim of
treating colon carcinoma metastases resulted in prolonged
survival [16,17]. The primary aim of the present study was to
evaluate the toxicity and secondly the therapeutic efficacy of
211At-labeledmAb on small solid tumors of colon carcinoma
in a syngeneic immunocompetent rat model. To the best of
our knowledge, 211At-mAbs have not previously been evalu-
ated in an immunocompetent animal model. The same ani-
mal model andmAb have previously been utilized for studies
of radioimmunotherapy with the β-emitting radionuclides
177Lu and 90Y [18,19].
Methods
Monoclonal antibody
BR96 (Seattle Genetics Inc., Seattle, WA, USA) is a chi-
meric (mouse/human) IgG1 mAb recognizing the Lewis Y
epitope. Lewis Y is expressed in several carcinomas, includ-
ing breast, gastrointestinal, pancreatic, non small cell lung,
cervical, and ovarian cancer, and in some melanomas. As
with many tumor-associated antigens, the epitope is also
expressed in some normal tissues, including the epithelial
cells of the gastrointestinal tract in humans [20] and in the
rat strain used in this study [19].
Radiochemistry
Astatine-211 was produced by irradiating stable bismuth
using the 209Bi(α,2n)211At reaction at the Cyclotron and
PET Unit, Rigshospitalet, Copenhagen, Denmark. After
irradiation, the target was transported to the Department
of Nuclear Medicine at Sahlgrenska University Hospital,
Gothenburg, Sweden, where the astatine was transformed
into a chemically useful form by dry distillation, as de-
scribed previously [21].
211At labeling of BR96 was performed essentially as
described previously [22]. Briefly, the antibody was first
reacted with the N-succinimidyl-3-(trimethylstannyl)
benzoate reagent to give the ε-lysyl-3-(trimethylstannyl)
benzamide BR96 immunoconjugate. After 30 min of in-
cubation with the reagent, the BR96 conjugate was iso-
lated in 0.1 M citrate buffer (pH 5.5) using a Sephadex
NAP-5 column. From the BR96 conjugate preparation,
800 μg was added to a vial containing 336 MBq of 211At ox-
idized by 15 μL N-iodosuccinimide (NIS; 67 μM) in metha-
nol with 1% acetic acid during vigorous agitation. After
1 min, 3 μL NIS (1 mg/mL) was added, and the reaction
mixture was incubated for 1 min before terminating the
reaction with 5 μL sodium ascorbate (50 mg/mL). The anti-
body fraction, 211At-BR96, was isolated using a Sephadex
NAP-5 column. To protect the antibody from radiolysis,the 0.9-mL product volume was eluted into a vial containing
0.1 mL phosphate buffered saline (PBS) with 10% bovine
serum albumin. Unlabeled BR96 was added to adjust the
mAb dose to 150 μg per animal.
The antigen-binding properties (immunoreactivity) of
211At-BR96 relative to BR96 were analyzed by determin-
ation of the equilibrium binding constant (Kd) by satur-
ation binding curve analysis as previously described [18],
using BN7005 cells as the target antigen. The immuno-
reactivity is given by the ratio Kd(BR96)/Kd(
211At-BR96).
Animal model
The BN7005-H1D2 cell line was originally established from
a colon carcinoma detected in a 1,2-dimethylhydrazine-
treated Brown Norway rat. The cell line expresses the
Lewis Y antigen both in vitro and in vivo. The survival frac-
tion after external irradiation with 2 Gy has been deter-
mined to be 0.5, which indicates moderate radiosensitivity
comparable to human colon carcinoma cell lines [23]. Cells
were cultured in RPMI 1640 medium supplemented with
10% fetal bovine serum, 1 mM sodium pyruvate, 10 mM
Hepes buffer (all from PAA Laboratories GmbH, Pasching,
Austria), and 14 mg/L gentamicin (Gibco, Invitrogen,
Carlsbad, CA, USA) at 37°C in a humidified environment
before harvesting by trypsin treatment and suspension in
supplemented medium prior to inoculation.
Immunocompetent male Brown Norway rats (Harlan La-
boratories, Horst, the Netherlands), with a body weight of
approximately 250 g, were inoculated with 3 × 105 BN7005-
H1D2 cells in 50 μL culturing medium between the periton-
eum and the abdominal muscle under anesthesia with
isoflurane (Abbott Scandinavia AB, Solna, Sweden). Tumor
growth was monitored by palpation and tumor measure-
ment with a digital caliper. The animals were housed under
standard conditions and fed pellets and fresh water ad
libitum. The experiment was approved by the regional ani-
mal ethics committee and followed Swedish legislation on
animal welfare and protection.
Dosimetry and estimation of maximum tolerable activity
The activities of 211At in this study were chosen with re-
spect to the absorbed dose to the bone marrow. In a
review on the toxicity of α-emitting radionuclides, Dahle
et al. [24] presented values for maximal tolerable doses to
the bone marrow (MTDBM) ranging from 0.4 to 7.6 Gy
for different α-emitters. Intravenous (i.v.) administration
of 211At-labeled antibodies to mice indicated values of
MTDBM from 2 to 4 Gy [25,26]. A value of 4 Gy was
chosen as the MTDBM in the present study, and the
absorbed dose to the bone marrow was estimated using
bone marrow uptake data from a previous biodistribution
study of 177Lu-BR96 in the same animal model [27]. Using
these 177Lu-BR96 uptake data (% injected activity/g tissue),
theoretical time-activity curves were obtained for 211At-
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total number of decays, Ã) of 211At. Assuming an
absorbed fraction of the α-particles, φα, to be 1 and in-
cluding contributions only from α-particles, the absorbed





where m denotes tissue mass, and Δα is the mean energy
released per 211At decay (here assumed to be 1.09 × 10−12 J).
The estimated mean absorbed dose to the bone marrow for
211At-BR96 was found to be 0.8 Gy/MBq. Using the assumed
MTDBM of 4 Gy, the corresponding maximum tolerable ac-
tivity that could be injected was 5 MBq.
Radioimmunotherapy
Two weeks (defined here as day 0) after inoculation, the
tumor-bearing rats were allocated to three groups (six
rats per group) with similar distributions of tumor size,
see Table 1. In addition, three rats without tumors were
included in each group to monitor toxicity without in-
fluence from tumor burden. The rats were injected with
either 150 μg of unlabeled BR96 in PBS (control group),
2.5 MBq 211At-BR96 corresponding to 9 MBq/kg body
weight (2.5 MBq group), or 5 MBq 211At-BR96 corre-
sponding to 19 MBq/kg body weight (5 MBq group).
The mAbs were administered via the tail vein under
anesthesia, and the injection volume was 0.4 mL.
Monitoring after treatment
Tumor sizes were measured twice weekly after treat-
ment. Tumor volumes were calculated as tumor length ×
width2 × 0.4. Tumors not palpable for at least one con-
secutive week were classified as undetectable. Body
weight was also recorded twice per week. Bone marrow
toxicity was monitored by counting red blood cells, white
blood cells, and platelets in arterial blood samples with a
Vet CA530 Medonic Cell Analyzer (Boule Medical,Table 1 Group characteristics at day 0 and injected activities
Treatment group Body weight (g) Tumor volume (m
Controls (unlabeled BR96)
Tumor (n = 6) 290 (282 to 300) 520 (282 to 640
Non-tumor (n = 3) 289 (281 to 296) -
2.5 MBq 211At-BR96
Tumor (n = 6) 272 (269 to 278) 475 (256 to 640
Non-tumor (n = 3) 276 (271 to 278) -
5 MBq 211At-BR96
Tumor (n = 6) 259 (247 to 266) 371 (176 to 520
Non-tumor (n = 3) 264 (259 to 267) -
IA, injected activity.Stockholm, Sweden) twice a week for the first 4 weeks,
then once weekly until the end of the study. Plasma was
sampled from animals without tumors for the analysis of
liver and kidney function markers.
Animals were monitored up to 100 days after treat-
ment as this was sufficient for detection of metastases in
previous work with animals followed up to 180 days post
injection (p.i.) [19]. The rats were sacrificed with an
overdose of isoflurane at the end of the study or when
the tumor exceeded 20 × 20 mm, body weight decreased
by >15%, or if the animal's general health was affected.
At the time of sacrifice, all animals were dissected sys-
tematically by the same person, and the number and lo-
cation of metastatic sites were noted. Tumor findings
detected at autopsy were fixed in 4% paraformaldehyde
and embedded in paraffin.Immunohistochemistry
The tumor findings were sectioned and stained with
hematoxylin and eosin for histological evaluation or exa-
mined immunohistochemically to evaluate BR96 target
antigen expression and proliferation. In short, sections were
dehydrated, and antigen retrieval was performed by heating
the slides in citrate buffer, pH 6. After washing in Tris-
buffered saline with 0.25% Tween 20 and blocking of
endogenous peroxidases with Peroxidase Blocking Solution
(Dako, Glostrup, Denmark), the sections were incubated
with 5 μg/mL BR96 in Antibody Diluent (Dako) overnight
or with Rabbit anti Ki67 (Clone SP6, NeoMarkers,
Fremont, CA, USA) for 2 h, all at room temperature in a
moist chamber. After washing, the secondary antibody don-
key F(ab)2 anti-human IgG-HRP (BR96) or donkey anti-
rabbit HRP (Ki67; both from Jackson ImmunoResearch
Laboratories, West Grove, PA, USA) in Antibody Diluent
was added to the sections and incubated for 3 h at room
temperature. Finally, diaminobenzidine (Dako) was added
before dehydration and mounting. The target antigen ex-
pression was evaluated in relation to tumor histology by(average values and ranges)
m3) Injected activity (MBq) IA/kg body weight (MBq/kg)
) - -
- -
) 2.5 (2.5 to 2.6) 9.3 (9.0 to 9.6)
2.4 (2.4 to 2.4) 8.8 (8.7 to 8.9)
) 5.0 (4.9 to 5.1) 19.2 (18.3 to 19.9)
4.8 (4.6 to 4.9) 18.0 (17.5 to 18.3)
Figure 1 Toxicity after i.v. administration of 211At-BR96. Body
weight normalized to day 0 (A), white blood cell count (B), and
platelet count (C). Error bars denote the standard error of the mean
after intravenous injection of 211At-BR96. Animals with inoculated
tumors were excluded from (B) and (C) in order to evade effects
from tumor burden being mistaken as toxicity.
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with complete cell membrane staining.
Statistical analyses
Prism 5.04 (GraphPad Software Inc., La Jolla, CA, USA)
was used for statistical analyses. Weight loss and blood
cell counts were analyzed with either one-way analysis of
variance (ANOVA) or two-way ANOVA with Bonferroni
multiple comparison post tests. Survival was analyzed
with the log-rank Mantel-Cox test.
Results
Radiochemistry
The radiochemical purity (RCP) was 97% according to
methanol precipitation. The non-decay-corrected radio-
chemical yield (RCY) was determined to be 78%, using
the relation
RCY ¼ Atot  RCP
Aadded
where Atot is the total activity eluted from the NAP-5
column, and Aadded is the activity added to the reaction.
The immunoreactivity, expressed as the ratio of the Kd
for BR96 and 211At-BR96, was 0.93 for both specific ac-
tivities. The Kd of
211At-BR96 was within the 95% confi-
dence interval of the Kd for BR96.
Toxicity
The administration of 2.5 and 5 MBq 211At-BR96
resulted in dose-dependent relative weight losses of 3%
(range 1% to 6%) and 5% (range 4% to 8%), respectively,
the nadir being seen on the first recording after treat-
ment (day 2 p.i.). This can be compared to a weight in-
crease of 1% in the control group (range −1% to 1%; p <
0.0001). The animals in the 2.5 MBq group showed full
recovery of weight within 1 week, whereas the animals
in the 5 MBq group showed a delayed progression in
weight compared to the control group (difference not
statistically significant) (Figure 1A).
The white blood cell counts decreased in a dose-
dependent manner; the nadir being seen on day 2 (first
sampling occasion) (p < 0.0001). Full recovery of white
blood cell counts was observed on days 19 (median,
range 15 to 22) and 33 (26 to 33) in the 2.5 and 5 MBq
groups, respectively (Figure 1B). On day 8, the platelet
count had decreased to approximately 50% of the base-
line in the 2.5 MBq group and to 25% in the 5 MBq
group (p < 0.0001) (Figure 1C). Platelet counts had re-
covered on day 19 (range 15 to 22) in the 2.5 MBq
group and on day 22 (range 19 to 26) in the 5 MBq
group. In one rat in each group given 211At, the number
of platelets started to decrease after initial recovery and
then remained at 25% to 50% of the initial value until
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cant variation in red blood cell counts between the three
groups (data not shown). Data from rats with and with-
out inoculated tumors were included in the statistical
analyses.
The levels of alanine transaminase (ALAT) and gamma
glutamyl transpeptidase (γGT) in plasma were used as
markers of liver function. ALAT remained unaffected by
treatment, whereas the level of γGT was elevated less
than 2.5 times the upper limit of normal level (grade 1
according to the National Cancer Institute Common Ter-
minology for Adverse Events version 4.0) for 3 weeks after
the administration of the higher activity of 211At-BR96.
The plasma levels of creatinine did not reveal any kidney
toxicity after radioimmunotherapy with 211At-BR96.Treatment outcome
Survival was significantly prolonged in groups given
211At-BR96 compared to the control group (p = 0.017)
(Figure 2A). Undetectable tumors were recorded in five
out of six animals in both groups given 211At-BR96 and
in one out of six animals in the control group, see
Table 2. Remaining tumors continued to grow except in
one animal in the 5 MBq group, which remained stable
until the end of the study (Figure 2B,C,D). One recurrent
local tumor was detected in each group given 211At-BR96,
in both cases after 3 weeks of non-palpable tumors. In allFigure 2 Survival and tumor growth after treatment. Survival of rats w
(A). Individual tumor volumes after treatment with unlabeled BR96 (B), 2.5groups, smaller tumors seemed to respond better to the
therapy, as has been observed by others [28,29].
Metastases were found in all treatment groups, most
commonly in the lymph nodes, but also in the liver and
spread throughout the abdomen. Metastases were
detected at autopsy in five animals in the control group
that were sacrificed between days 16 and 35 due to high
primary tumor burden. In the 2.5 MBq group, one ani-
mal with a remaining primary tumor sacrificed on day
33 due to signs of metastatic disease and one that was
sacrificed on day 82 due to the burden of the recurrent
tumor showed metastases at autopsy. Another rat in this
group, sacrificed at the end of the study without any pri-
mary or recurrent tumor, was found to have a lymph
node metastasis. In the 5 MBq group, one rat with re-
current disease sacrificed due to tumor burden at the
end of the study was found to have two lymph node me-
tastases, while one rat with stable disease was free from
detectable metastases. An additional rat in this group,
without a primary tumor, was found to have a lymph
node metastasis at the end of the study.
All tumor findings contained viable and proliferating
tumor cells. Both primary tumors and detected metasta-
ses in the control group showed high expression of the
BR96 target antigen, with complete membrane staining
of at least >50% of all tumor cells; in half of the samples,
the number of stained cells was >90% (Figure 3A). The
target antigen was detected in more than 50% of theith established colon carcinoma tumors after treatment with 211At-BR96
MBq 211At-BR96 (C), and 5 MBq 211At-BR96 (D).
Table 2 Tumor response after treatment with 211At-BR96
Treatment group Undetectable tumors Stable tumors Progressing tumors Recurrence Metastases at autopsy
Controls (unlabeled BR96) 1/6 0/6 5/6 0/1 5/6
2.5 MBq 211At-BR96 5/6 0/6 1/6 1/5 3/6
5 MBq 211At-BR96 5/6 1/6 0/6 1/5 2/6
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treated groups (Figure 3B,C,D). No tumor finding lacked
expression of the target antigen; however, the number of
positive cells was less than 10% in one-third of the tis-
sues. The antigen was commonly detected in larger areas
rather than on single cells surrounded by negative cells.
Areas with weak staining were observed in several of the
tissue sections. There were no trends regarding number
of antigen-expressing tumor cells regarding the metastatic
site. The two recurred primary tumors had lower expres-
sion compared to the stable and progressing tumors.
Discussion
In this animal study, the concept of targeted alpha the-
rapy was shown to be both tolerable and efficient in the
treatment of established colon carcinoma. The activities
administered were based on an estimate of the maximal
tolerable dose to bone marrow, using historical 177Lu-
BR96 biodistribution data for the theoretical calculation
of the absorbed dose resulting from treatment with
211At-BR96 [27]. Both administered activities, 2.5 andFigure 3 Antigen expression after treatment. The target antigen detect
2.5 MBq 211At-BR96 (B), an abdominal metastasis in a rat treated with 2.5 M
5 MBq 211At-BR96 (D). (B) and (D) are from the same rat.5 MBq/animal (9 and 19 MBq/kg body weight), were
tolerated with regard to myelotoxicity, kidney, liver, and
general toxicity. The minor tendency towards increased
hematologic toxicity and the delayed weight progression
in the group given 5 MBq indicate that this activity was
probably close to the maximal tolerable activity.
The treatment resulted in undetectable tumors in five
out of six rats in both groups treated with 211At-BR96.
Survival was prolonged compared to the control group
given unlabeled mAb. The increased survival in the
group given 5 MBq 211At-BR96 was not significantly dif-
ferent from that in the group given 2.5 MBq. Due to the
efficacy of the administration of 2.5 MBq, it is difficult
to motivate the use of higher activity.
Assuming a heterogeneous tumor uptake of the anti-
body, as has recently been found for 177Lu-BR96 [30],
due to physiological factors such as the distribution of
functional blood vessels and high interstitial fluid pres-
sure [31], eradication of all viable tumor cells by short-
range α-particles could be impaired. The limited range
may be compensated to some extent by the bystandered in a tumor treated with unlabeled BR96 (A), a tumor treated with
Bq 211At-BR96 (C), and a lymph node metastasis in a rat treated with
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compromised nutrition may also enhance the antitumor
effect [33-35].
Targeted alpha therapy is generally regarded as being
more appropriate for loco-regional treatment since the
short physical half-life and the kinetics after i.v. adminis-
tration of intact mAbs could mean that most decays have
occurred before binding to the target antigen on tumor
cells [36]. This also applies to our animal model, in which
the maximal tumor uptake was observed 24 h p.i. [30].
Therefore, the strong antitumor response, resulting in
undetectable tumors in five out of six animals in both
groups given 211At-mAb seen in the present study, was
not expected. Recent mouse studies on i.v. therapy of
small solid tumors using 211At-labeled antibodies [37] in-
dicated that mean absorbed tumor doses above 10 Gy
were required for the eradication of small solid tumors.
No experimental data on tumor uptake of 211At-BR96
were available for the estimation of the absorbed dose to
the tumors in the present study. However, using tumor
uptake data for 177Lu-BR96, the estimated mean absorbed
dose to the tumors would be approximately 9.6 and
4.8 Gy, for activities of 5 and 2.5 MBq, respectively.
The antitumor response could have been enhanced by
the mAb itself due to the initiation of antibody-dependent
cell-mediated cytotoxicity and/or complement-dependent
cytotoxicity [38,39]. The presence of such effects was
demonstrated in the control group, in which one tumor
disappeared completely and four other tumors showed a
small initial response, as has been seen previously in our
animal model [30]. An advantage of syngeneic immuno-
competent animal models is the possibility to study the
synergistic effects of radioimmunotherapy and the adap-
tive immune system.
Metastases were detected in five out of six rats treated
with unlabeled BR96, despite the shorter survival time,
and in approximately half of the animals in the groups
given 211At-BR96. All metastases demonstrated antigen
expression, but to a much lower extent in the groups
given 211At-BR96. This may be the result of the elimin-
ation of tumor cells with sustained antigen expression
and repopulation by clones of cells lacking the target
antigen, thereby reducing the possibility of eradicating
metastases by repeating the treatment. It is currently not
known whether tumor cells are disseminated and spread
before or during radioimmunotherapy in our animal
model since the untreated animals are often sacrificed
before any metastases can be detected due to heavy pri-
mary tumor burden.
The targeted alpha therapy using 211At-labeled mAbs in
this study resulted in a comparable rate of CR in tumor-
bearing rats to that found when using 177Lu-labeled BR96
in the same rat tumor model [18]. The proportion of
animals with detectable disseminated disease was around50% after both α and β radioimmunotherapy. Beta-emitting
radionuclides are generally regarded as being better suited
for the treatment of solid tumors due to their longer par-
ticle range than α-emitting radionuclides, reducing the
effect of heterogeneous tumor distribution. However, this
property limits the effectiveness against small cell clusters
and singe cells [40] as most of the energy is deposited
outside the tumor. One therapeutic strategy could be to
combine α- and β-emitting radionuclides to utilize their
different properties. It would also be relevant to develop
an orthotopic metastasis model with our syngeneic sys-
tem, with smaller tumor lesions in the liver and/or lungs
instead of the comparably larger solid tumors used in the
present study. Such a study on microscopic metastases in
the liver has been performed with 177Lu-labeled mAbs in
a model of colon cancer [16]. The results of that study
showed increased survival and delayed tumor growth in
animals treated with radioimmunotherapy, but the cure
rate was not affected. A comparison of α and β radio-
immunotherapy in such a model would be useful in
providing evidence of the suitability of the different radio-
nuclides regarding their physical properties in the treat-
ment of metastases.Conclusions
Treatment with 211At-mAbs was tolerable with respect to
toxicity at activity levels resulting in undetectable tumors
in a syngeneic rat colon carcinoma model. The results
demonstrate that radioimmunotherapy with 211At can be
an effective treatment modality for well-established and
well-vascularized tumors up to a size of 10 to 15 mm, but
did not affect the development of metastatic disease.
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